Progress in the treatment of malignant ascites

Yiqiu Wang; Yunting Sun; Xinyue Li; Xiaoli Yu; Keying Zhang; Jinglei Liu; Qingchang Tian; Honghua Zhang; Xiao Du; Shuling Wang

doi:10.1016/j.critrevonc.2023.104237

Progress in the treatment of malignant ascites

Crit Rev Oncol Hematol. 2024 Feb:194:104237. doi: 10.1016/j.critrevonc.2023.104237. Epub 2023 Dec 19.

Authors

Affiliations

¹ Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Hangzhou, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou, Zhejiang 311121, China; School of Pharmacy, Hangzhou Normal University, Hangzhou, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.
² Hangzhou TCM Hospital Afflitiated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang 311121, China. Electronic address: syt182@163.com.
³ Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Hangzhou, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou, Zhejiang 311121, China; School of Pharmacy, Hangzhou Normal University, Hangzhou, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China. Electronic address: 20230041@hznu.edu.cn.
⁴ Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Hangzhou, Zhejiang 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou, Zhejiang 311121, China; School of Pharmacy, Hangzhou Normal University, Hangzhou, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China. Electronic address: wsling222@163.com.

PMID: 38128628
DOI: 10.1016/j.critrevonc.2023.104237

Abstract

Malignant ascites occurs as a symptom of the terminal stage of cancer, affecting the quality of life through abdominal distension, pain, nausea, anorexia, dyspnea and other symptoms. We describe the current main drug treatments in addition to surgery according to the traditional and new strategies. Traditional treatments were based on anti-tumor chemotherapy and traditional Chinese medicine treatments, as well as diuretics to relieve the patient's symptoms. New treatments mainly involve photothermal therapy, intestinal therapy and targeted immunity. This study emphasizes that both traditional and new therapies have certain advantages and disadvantages, and medication should be adjusted according to different periods of use and different patients. In conclusion, this article reviews the literature to systematically describe the primary treatment modalities for malignant ascites.

Keywords: Malignant ascites; Photodynamic and photothermal therapy; Targeted immunotherapy; Traditional Chinese medicine; Traditional and new treatment.

Publication types

Review

MeSH terms

Ascites* / drug therapy
Ascites* / therapy
Humans
Immunotherapy
Peritoneal Neoplasms* / complications
Peritoneal Neoplasms* / therapy
Quality of Life